Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.

Date publication

juin 2017

Journal

Clinical pharmacokinetics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DELMER Alain

Tous les auteurs :
Tout M, Gagez AL, Leprêtre S, Gouilleux-Gruart V, Azzopardi N, Delmer A, Mercier M, Ysebaert L, Laribi K, Gonzalez H, Paintaud G, Cartron G, Ternant D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27783363

Résumé

Rituximab is an anti-CD20 monoclonal antibody approved in the first-line treatment of patients with chronic lymphocytic leukemia (CLL). Rituximab pharmacokinetics shows a time dependency possibly related to changes in the target antigen amount over time. The purpose of this study was to quantify the influence of both CD20 antigenic mass and the FcγRIIIA genetic polymorphism on rituximab pharmacokinetics in CLL.

Mots clés

Antigens, CD20, metabolism, Antineoplastic Agents, blood, B-Lymphocytes, metabolism, Body Surface Area, Female, Genotype, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, drug therapy, Lymphocyte Count, Male, Middle Aged, Models, Biological, Polymorphism, Genetic, Receptors, IgG, genetics, Rituximab, blood

Référence

Clin Pharmacokinet. 2017 06;56(6):635-647